Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has resumed patient dosing in its U.S. Phase III study of TG-C for the treatment of knee osteoarthritis (OA). Also Read: Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome The two pivotal… Continue reading Kolon Tissuegene Resumes TG-C Phase III Studies in the US